SDZ IMM 125: structure given in first source; a hydroxyethyl derivative of serine(8)-cyclosporine; inhibits proliferation and functions of lymphocytes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6436153 |
| CHEMBL ID | 217642 |
| SCHEMBL ID | 1229430 |
| MeSH ID | M0204383 |
| Synonym |
|---|
| sdz imm 125 |
| oxeclosporin |
| cyclo(((2s,3r,4r,6e)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-l-2-aminobutyryl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl-l-alanyl-o-(2-hydroxyethyl)-d-seryl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl) |
| oxeclosporin [inn] |
| CHEMBL217642 |
| (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-12-(2-hydroxyethoxymethyl)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,15,19,25,28-octamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritr |
| r7988d03jm , |
| 135548-15-1 |
| unii-r7988d03jm |
| oxeclosporin [who-dd] |
| SCHEMBL1229430 |
| sdz-imm 125 |
| DTXSID10873121 |
| Q27287882 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The disposition kinetics of IMM in plasma, blood cells, and various tissues of the rat was characterized by a physiologically based pharmacokinetic (PBPK) model; the model was then applied to predict the disposition kinetics in dog and human." | ( Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. Bruelisauer, A; Kawai, R; Lemaire, M; Niederberger, W; Rowland, M; Steimer, JL, 1994) | 0.52 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " As the bioavailability of the drug was considered to be greater than that of cyclosporin, it was hoped that lower doses could be used with the avoidance of nephrotoxicity." | ( A new cyclosporin derivative, SDZ-IMM-125, prolongs renal allograft survival in dogs. al-Shaibani, K; Dunnill, MS; Esmeraldo, R; Gray, DW; Mason, J; Morris, PJ, 1995) | 0.29 |
| " A comparison of CSA to its hydroxyethyl derivative SDZ IMM 125 (IMM) as to bioavailability to epidermal and dermal cells and the potential for inactivation by biotransformation was investigated using a human dermal skin model (skin2 ZK1100) and a barrier function model (skin2 ZK 1300)." | ( Uptake and metabolism of cyclosporin A and SDZ IMM 125 in the human in vitro skin2 dermal and barrier function models. Biggi, WA; Dannecker, R; Fischer, V; Vickers, AE, 1995) | 0.8 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID102709 | In vitro inhibition of interleukin-2 (IL-2) production induced by stimulating lymphocytes derived from mouse spleens with the mitogen canavalin A | 1995 | Journal of medicinal chemistry, May-26, Volume: 38, Issue:11 | Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin. |
| AID102701 | In vitro efficacy to suppress lymphocyte proliferation as measured by the incorporation of a labeled precursor ([3H]- thymidine) into DNA in Mixed Lymphocyte reaction (MLR). | 1995 | Journal of medicinal chemistry, May-26, Volume: 38, Issue:11 | Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin. |
| AID102700 | In vitro efficacy on humoral immune response by Mishell-Dutton assay (MD). | 1995 | Journal of medicinal chemistry, May-26, Volume: 38, Issue:11 | Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (80.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (4.55%) | 5.53% |
| Reviews | 1 (4.55%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||